Learn About Osteopetrosis

What is the definition of Osteopetrosis?

Osteopetrosis is a bone disease that makes bone tissue abnormally compact and dense and also prone to breakage (fracture). Researchers have described several major types of osteopetrosis, which are usually distinguished by their pattern of inheritance: autosomal dominant or autosomal recessive. The different types of the disorder can also be distinguished by the severity of their signs and symptoms.

What are the causes of Osteopetrosis?

Variants (also called mutations) in at least eight genes cause the various types of osteopetrosis. Variants in the CLCN7 gene are responsible for about 75 percent of cases of autosomal dominant osteopetrosis, 10 to 15 percent of cases of autosomal recessive osteopetrosis, and all known cases of intermediate autosomal osteopetrosis. TCIRG1 gene variants cause about 50 percent of cases of autosomal recessive osteopetrosis. Variants in other genes are less common causes of autosomal dominant and autosomal recessive forms of the disorder.  In about 30 percent of all cases of osteopetrosis, the cause of the condition is unknown.

How prevalent is Osteopetrosis?

Autosomal dominant osteopetrosis is the most common form of the disorder, affecting about 1 in 20,000 people. Autosomal recessive osteopetrosis is rarer, occurring in an estimated 1 in 250,000 people.

Is Osteopetrosis an inherited disorder?

Osteopetrosis can have several different patterns of inheritance. Most commonly, the disorder has an autosomal dominant inheritance pattern, which means one copy of an altered gene in each cell is sufficient to cause the disorder. Most people with autosomal dominant osteopetrosis inherit the condition from an affected parent.

Who are the top Osteopetrosis Local Doctors?
Ansgar S. Schulz
Elite in Osteopetrosis
Elite in Osteopetrosis
Marburger Str. 85, 
Kassel, HE, DE 

Ansgar Schulz practices in Kassel, Germany. Schulz is rated as an Elite expert by MediFind in the treatment of Osteopetrosis. Their top areas of expertise are Osteopetrosis, Severe Combined Immunodeficiency (SCID), CLN2 Disease, Bone Marrow Transplant, and Splenectomy.

Elite in Osteopetrosis
Endocrinology
Elite in Osteopetrosis
Endocrinology

University Medical Diagnostic Associates Inc

550 N University Blvd, 
Indianapolis, IN 
Languages Spoken:
English

Michael Econs is an Endocrinologist in Indianapolis, Indiana. Dr. Econs is rated as an Elite provider by MediFind in the treatment of Osteopetrosis. His top areas of expertise are Osteosclerosis Autosomal Dominant, Osteopetrosis, X-Linked Hypophosphatemia, and Hypophosphatemia.

 
 
 
 
Learn about our expert tiers
Learn More
Morten A. Karsdal
Elite in Osteopetrosis
Elite in Osteopetrosis
Herlev, DK 

Morten Karsdal practices in Herlev, Denmark. Mr. Karsdal is rated as an Elite expert by MediFind in the treatment of Osteopetrosis. His top areas of expertise are Cirrhosis, Osteoarthritis, Arthritis, Kidney Transplant, and Endoscopy.

What are the latest Osteopetrosis Clinical Trials?
A Phase II Study of Reduced Intensity Conditioning in Pediatric Patients and Young Adults ≤55 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood, Bone Marrow, or Peripheral Blood Stem Cell Transplantation

Summary: The objective of this study is to evaluate the efficacy of using a reduced-intensity condition (RIC) regimen with umbilical cord blood transplant (UCBT), double cord UCBT, matched unrelated donor (MUD) bone marrow transplant (BMT) or peripheral blood stem cell transplant (PBSCT) in patients with non-malignant disorders that are amenable to treatment with hematopoietic stem cell transplant (HSCT). ...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Clinical Validation of a Self-questionnaire in Adults With Osteoporosis

Summary: Osteoporosis is a multifactorial disease in which genetic predispositions play a key role in its development. A better understanding of family history and clinical manifestations among first- and second-degree relatives can help improve early detection and personalized care for at-risk patients. To this end, we will test a self-administered questionnaire previously developed by our research team. ...

Who are the sources who wrote this article ?

Published Date: September 01, 2010
Published By: National Institutes of Health